DepoCyte Unión Europea - español - EMA (European Medicines Agency)

depocyte

pacira limited - citarabina - neoplasmas meníngeos - agentes antineoplásicos - tratamiento intratecal de la meningitis linfomatosa. en la mayoría de los pacientes, dicho tratamiento será parte de la paliación sintomática de la enfermedad.

Nyxoid Unión Europea - español - EMA (European Medicines Agency)

nyxoid

mundipharma corporation (ireland) limited - la naloxona clorhidrato dihidratado - trastornos relacionados con los opioides - todos los demás productos terapéuticos - nyxoid está pensado para la administración inmediata como tratamiento de emergencia para la sobredosis de opiáceos o sospechada como se manifiesta por depresión del sistema nervioso central y respiratoria en contextos no médicos y de salud. nyxoid is indicated in adults and adolescents aged 14 years and over. nyxoid is not a substitute for emergency medical care.

OSTEOPEN 100 mg/ml SOLUCION INYECTABLE PARA PERROS España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

osteopen 100 mg/ml solucion inyectable para perros

chanelle pharmaceuticals manufacturing limited - pentosano polisulfato sodio - soluciÓn inyectable - pentosano polisulfato sodio 100mg - pentosano polisulfato sódico - perros

Jalra Unión Europea - español - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptina - diabetes mellitus, tipo 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 y 5. 1 para datos disponibles sobre diferentes combinaciones).

Dapagliflozin Viatris Unión Europea - español - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas en diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 y 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.